

Physiomics plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK

Tel 01865 784980
Fax 08701 671931

11 November 2011

Physiomics plc

("Physiomics" or "the Company")

**Physiomics to present on R&D Developments at the 2011 EORTC-NCI-AACR symposium on
"Molecular targets and Cancer Therapeutics"**

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics", taking place at the Moscone Center West, San Francisco, California on 12-16 November 2011. Dr Eric Fernandez, Project Leader at Physiomics, will present on a prototype version of an anti-cancer drug combination and regimen database. Dr Frances Brightman, Senior Scientist at Physiomics, will present on the use of three-dimensional cell cultures to calibrate Virtual Tumour™.

More information about the conference may be found at:

<http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics.aspx>

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are pleased to present these developments to the major players in the oncology field. This research is part of our ongoing effort to reduce and simplify the data required to calibrate our models."

Enquiries:

Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980

WH Ireland Limited

Physiomics plc

Registered in England and Wales Number 4225086

Registered Office: The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK

Katy Mitchell
+44 (0) 161 832 2174

Information on Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behavior to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as \$242 million, from the current estimate of around \$800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002